Optimizing the anticoagulation therapy is of pivotal importance in patients with a malignant
tumor, as venous thromboembolism (VTE) has become the second-leading cause of death …

Epithelial–mesenchymal transition (EMT) is an important biological process contributing to
kidney fibrosis and chronic kidney disease. This process is characterized by decreased …

The thrombosis-related diseases are one of the leading causes of illness and death in the
general population, and despite significant improvements in long-term survival due to …

Chronic kidney disease (CKD) with diverse aetiologies is emerging as a challenging kidney
disorder associated with inflammation and interstitial fibrosis. Carvacrol (CVL) is a bioactive …

Pancreatitis, the inflammatory disorder of the pancreas, has no specific therapy. Genetic,
biochemical, and animal model studies revealed that trypsin plays a central role in the onset …

Fibrosis, also known as organ scarring, describes a pathological stiffening of organs or
tissues caused by increased synthesis of extracellular matrix (ECM) components. In the past …

Protease-activated receptor 4 (PAR4) is a G protein-coupled receptor activated by thrombin.
In the platelet, response to thrombin PAR4 contributes to the predominant procoagulant …

Anticoagulant-related nephropathy (ARN) is a novel and not well-studied cause of acute
kidney injury (AKI). The prevalence of ARN varies significantly between studies and is …

Protease activated receptors (PARs) are among the first receptors shown to transactivate
other receptors: noticeably, these interactions are not limited to members of the same family …

Background This study aims to investigate the effects of different direct oral anticoagulants
on experimental renal injury induced by temporary infrarenal aortic occlusion. Methods A …